The Hindu Business Line : Ranbaxy partners Sirtex to sell liver cancer drug

New Delhi, Sept. 24 Ranbaxy Laboratories Ltd has entered into an exclusive in-licensing agreement with Australian company Sirtex Medical Pvt Ltd (Sirtex) to sell the latter’s registered product for liver cancer.

The ten-year-old Sirtex specialises in research and development work in therapeutic segment.

SIR-Spheres, approved by the US Food and Drug Authority, is used in the treatment of patients with inoperable tumours from primary colorectal cancer that has spread to the liver, said Ranbaxy in a statement.

Ranbaxy has acquired the right to market the product in India, Bangladesh, Sri Lanka and Nepal. “We are pleased to partner with Sirtex, Australia, for this unique, high technology product SIR-Spheres… The agreement will enable Ranbaxy to further strengthen our position in the oncology segment,” said Mr Sanjeev Dani, Senior Vice-President and Regional Director, Asia and CIS, Ranbaxy. SIR-Spheres are biocompatible radio-active micro-spheres that contain yttrium-90 and emit beta radiation.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Essar to invest $210 m to buy 6 supramax

Carlsberg all-malt beer launched

Clarification on HUL buyback

Blackstone investment in NCCL okayed

MRPL pays dividend to HPCL

IVRCL bags orders worth Rs 394 cr

Norit bags Rs 11.2-cr deals

Excellence award for ONGC

India Cements rejigs board; 3 new directors inducted

LB India buys stake in Genus Overseas

Bajaj Auto moves ahead on 4-wheeler project

ONGC Videsh signs contract for Myanmar blocks

Norsk may pick up stake in more ONGC blocks

Ranbaxy partners Sirtex to sell liver cancer drug

IVRCL to enter mining soon

Indian Oil set to enhance refining capacity

ONGC plans Mumbai field Phase II redevelopment

Suzuki plans rolling out new models next year-end